Ethics in nanomedicine.
暂无分享,去创建一个
[1] D. Resnik,et al. Ethical issues in clinical trials involving nanomedicine. , 2007, Contemporary clinical trials.
[2] N. Biller-Andorno,et al. Nanomedicine–emerging or re-emerging ethical issues? A discussion of four ethical themes , 2007, Medicine, health care, and philosophy.
[3] Lang Tran,et al. Safe handling of nanotechnology , 2006, Nature.
[4] Volker Wagner,et al. The emerging nanomedicine landscape , 2006, Nature Biotechnology.
[5] Ken Donaldson,et al. Resolving the nanoparticles paradox. , 2006, Nanomedicine.
[6] K K Jain,et al. Role of nanotechnology in developing new therapies for diseases of the nervous system. , 2006, Nanomedicine.
[7] P. Werfel. The pursuit of perfection. , 2006, JEMS : a journal of emergency medical services.
[8] J. Darbyshire,et al. Injury to research volunteers--the clinical-research nightmare. , 2006, The New England journal of medicine.
[9] B. Strom,et al. How the US drug safety system should be changed. , 2006, JAMA.
[10] Robert Combes,et al. TGN1412: Time to Change the Paradigm for the Testing of New Pharmaceuticals , 2006, Alternatives to laboratory animals : ATLA.
[11] Kristy Mills,et al. Getting the best from nanotechnology: approaching social and ethical implications openly and proactively , 2005, IEEE Technol. Soc. Mag..
[12] Wolfgang Kreyling,et al. Ultrafine Particles Cross Cellular Membranes by Nonphagocytic Mechanisms in Lungs and in Cultured Cells , 2005, Environmental health perspectives.
[13] Armin Grunwald,et al. Nanotechnology — A new field of ethical inquiry? , 2005, Science and engineering ethics.
[14] G. Oberdörster,et al. Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles , 2005, Environmental health perspectives.
[15] M Sugisaka,et al. Nanotechnology on duty in medical applications. , 2005, Current pharmaceutical biotechnology.
[16] P. Hoet,et al. Nanoparticles – known and unknown health risks , 2004, Journal of nanobiotechnology.
[17] Theresa M Allen,et al. Advantages of liposomal delivery systems for anthracyclines. , 2004, Seminars in oncology.
[18] F. Martin,et al. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. , 2004, Seminars in oncology.
[19] D. Resnik. Fair Drug Prices and the Patent System , 2004, Health Care Analysis.
[20] N. Fost,et al. hGH for short stature: ethical issues raised by expanded access. , 2004, The Journal of pediatrics.
[21] Arthur S Slutsky,et al. Data safety and monitoring boards. , 2004, The New England journal of medicine.
[22] S. Krown. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Jenny R. Roberts,et al. Skin as a route of exposure and sensitization in chronic beryllium disease. , 2003, Environmental health perspectives.
[24] D. Podzamczer,et al. Response to Liposomal Doxorubicin and Clinical Outcome of HIV-1–Infected Patients with Kaposi’s Sarcoma Receiving Highly Active Antiretroviral Therapy , 2001, HIV clinical trials.
[25] U. Hengge,et al. Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin. , 2001, European journal of cancer.
[26] D. Resnik. Developing drugs for the developing world: an economic, legal, moral, and political dilemma. , 2001, Developing world bioethics.
[27] D. Osoba,et al. Effect of Treatment on Health-Related Quality of Life in Acquired Immunodeficiency Syndrome (AIDS)-Related Kaposi's Sarcoma: A Randomized Trial of Pegylated-Liposomal Doxorubicin Versus Doxorubicin, Bleomycin, and Vincristine , 2001, Cancer investigation.
[28] R. Mitsuyasu,et al. AIDS-related Kaposi's sarcoma: current treatment options, future trends. , 2000, Oncology.
[29] C. Grady,et al. What makes clinical research ethical? , 2000, JAMA.
[30] S. Remick,et al. AIDS-related Kaposi's sarcoma: a phase II study of liposomal doxorubicin. The TLC D-99 Study Group. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] M A Fischl,et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] F. Goebel,et al. Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. , 1998, European journal of medical research.
[33] F. Mulcahy,et al. Treatment of Kaposi's sarcoma with liposomal doxorubicin. , 1995, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[34] S. Cohen. Human relevance of animal carcinogenicity studies. , 1995, Regulatory toxicology and pharmacology : RTP.
[35] P. Kern,et al. Liposomal doxorubicin in AIDS-related Kaposi's sarcoma: long-term experiences , 1994, The clinical investigator.
[36] D. Maloney. Toxicity tests in animals: extrapolating to human risks. , 1993, Environmental health perspectives.
[37] F. Martin,et al. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. , 1993, The American journal of pathology.
[38] E. Beck,et al. Changing disease patterns in patients with AIDS in a referral centre in the United Kingdom: the changing face of AIDS. , 1991, BMJ.
[39] R. K. Reynolds,et al. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice , 1988, Nature.
[40] A. Cornish-Bowden. The pursuit of perfection , 2004 .
[41] M. Mehlman. How will we regulate genetic enhancement? , 1999, Wake Forest law review.
[42] F. Goebel,et al. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. , 1994, Journal of acquired immune deficiency syndromes.
[43] D Tomlinson,et al. Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS. , 1994, Clinical oncology (Royal College of Radiologists (Great Britain)).
[44] M Stürzl,et al. Liposomal doxorubicin in the treatment of AIDS-associated Kaposi's sarcoma: clinical, histological and cell biological evaluation. , 1994, Research in virology.
[45] R. Miller,et al. Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcoma. , 1993, Clinical oncology (Royal College of Radiologists (Great Britain)).